Amarin Corporation plc - American Depositary Shares (AMRN)

Amarin Corporation (NASDAQ: AMRN) shares are trading higher Tuesday after the company announced a long-term exclusive license and supply agreement with Recordati S.p.A. to commercialize its cardiovascular drug VAZKEPA (icosapent ethyl) across 59 countries in Europe.

Amarin signs $175 million Vazkepa deal with Recordati, plans global restructuring and targets $70 million in cost cuts to improve cash flow

The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

AMRN earnings call for the period ending December 31, 2024.

AMRN earnings call for the period ending September 30, 2024.

AMRN earnings call for the period ending June 30, 2024.

Discover the top breakthrough stocks under $10 with strong fundamentals and strategic advantages to hit massive upside.

A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides.

AMRN earnings call for the period ending March 31, 2024.

AMRN stock results show that Amarin Corp beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

There was unambigously good news about the company's single commercialized medication.

AMRN earnings call for the period ending December 31, 2023.

Amarin's Q4 2023 financials: Revenues at $74.71 million, beating consensus. US net product revenue is $64.9 million, down Y/Y. CEO Patrick Holt shares operational progress, including European market signs. Amarin initiates a $50 million buyback, on track for $40 million in annual savings.

Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results.